<?xml version='1.0' encoding='utf-8'?>
<document id="24056785"><sentence text="Evaluation of utility of pharmacokinetic studies in phase I trials of two oncology drugs." /><sentence text="There are many phase I trials of oncology drug combinations, very few of which report clinically significant pharmacokinetic interactions" /><sentence text=" We hypothesized that the utility of such pharmacokinetic drug-drug interaction (DDI) studies is low in the absence of a mechanistic hypothesis" /><sentence text="" /><sentence text="We retrospectively reviewed 152 phase I (two drug) combination studies published between 2007 and 2011" /><sentence text="" /><sentence text="Only 28 (18%) studies had an implicit or explicit rationale, either inhibition/induction of a drug-metabolizing enzyme or transporter, cosubstrates for the same enzyme or transporter, potential for end-organ toxicity, or protein binding" /><sentence text=" Only 12 (8%) studies demonstrated a statistically significant DDI, on the basis of change in clearance (or area under the curve) of parent drug and/or active metabolite" /><sentence text=" There was a strong association between a rationale and a demonstrable drug interaction, as only 2% of studies without a rationale demonstrated a DDI, compared with 32% of studies with a rationale (Fisher exact test; P &lt; 10(-6))" /><sentence text="" /><sentence text="DDI studies should not be routinely performed as part of phase I trials of oncology combinations" /><sentence text="" /></document>